Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company Drug

Merck Ends Phase III Keytruda Studies in NSCLC and cSCC Due to Insufficient Results

Fineline Cube Aug 30, 2024

US-based Merck, Sharp & Dohme Inc. (NYSE: MRK) announced the discontinuation of two Phase III...

Company

BioMarin to Cut 225 Jobs Amid Challenges in Gene Therapy Commercialization

Fineline Cube Aug 30, 2024

US-based BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is navigating a challenging period marked by difficulties in...

Company Deals Medical Device

MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion

Fineline Cube Aug 30, 2024

China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co.,...

Company Drug

Tonghua Golden-Horse, UCB Seek China Approvals for Alzheimer’s, Myasthenia Gravis Drugs

Fineline Cube Aug 30, 2024

China’s Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. and Belgium-based UCB (FRA: UNC) are seeking marketing...

Company

Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024

Fineline Cube Aug 30, 2024

Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its...

Company Drug

Doma Biopharmaceutical Receives FDA Clearance for Phase I Trial of EGFR-MET Targeting ADC, DM005

Fineline Cube Aug 30, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a Chinese pharmaceutical firm, has received approval from the U.S....

Company Drug

Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials

Fineline Cube Aug 30, 2024

BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...

Company Deals

AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million

Fineline Cube Aug 30, 2024

QINGDAO—AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced a further investment in its...

Company Medical Device

NMPA Suspends Jeisys Medical Inc.’s Nd:YAG Laser Equipment Over Quality Concerns

Fineline Cube Aug 30, 2024

BEIJING—The National Medical Products Administration (NMPA) of China has issued a notification to immediately suspend...

Company Drug

CNGB Virogin’s VG161 On Track for Breakthrough Designation in China for Advanced Liver Cancer

Fineline Cube Aug 30, 2024

BEIJING—CNGB Virogin, a joint venture between Virogin Biotech and China National Biotec Group, is poised...

Policy / Regulatory

China’s Healthcare Statistics Show Improvements in Life Expectancy and Access to Medical Services

Fineline Cube Aug 30, 2024

BEIJING—The National Health Commission (NHC) of China has published the “China’s Healthcare Statistical Communique 2023,”...

Company

Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1

Fineline Cube Aug 30, 2024

SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first...

Company

Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight

Fineline Cube Aug 30, 2024

HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for...

R&D

American Government Funds Bolster Chinese Inventors’ Patents, According to USPTO Data

Fineline Cube Aug 30, 2024

WASHINGTON—A Reuters investigation into the United States Patent and Trademark Office (USPTO) data has uncovered...

Company

GeneQuantum Appoints Dr. Lingyu Zhu as Chief Business Strategy and Development Officer

Fineline Cube Aug 30, 2024

SUZHOU—GeneQuantum, a leading player in the biotech industry known for its cutting-edge enzymatic site-specific conjugation...

Policy / Regulatory

Jiangxi Healthcare Security Administration Launches Initiative to Widen Drug Availability

Fineline Cube Aug 29, 2024

JIANGXI—In a strategic move to enhance drug accessibility, the Healthcare Security Administration (HSA) bureau of...

Company Legal / IP

China’s Supreme Court Deals Blow to Sanofi’s Aubagio, Confirms Patent Cancellation

Fineline Cube Aug 29, 2024

BEIJING—In a recent development for the pharmaceutical industry, Sanofi’s multiple sclerosis therapy Aubagio (teriflunomide) has...

Company Deals

Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases

Fineline Cube Aug 29, 2024

NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE),...

Company Deals

Sackler-Owned Mundipharma Fails to Secure $1 Billion Valuation for China Unit

Fineline Cube Aug 29, 2024

LONDON—Mundipharma International Ltd., the UK-based pharmaceutical firm with ties to the Sackler family of the...

Company Drug

Sinopharm and Ruidio Pharmaceutical Advance in Priority Review for Innovative Drugs and Vaccines

Fineline Cube Aug 29, 2024

BEIJING—The Center for Drug Evaluation (CDE) has indicated that two Chinese companies, Foshan Ruidio Pharmaceutical...

Posts pagination

1 … 337 338 339 … 698

Recent updates

  • Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
  • TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
  • Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
  • Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
  • Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.